NCT07033182View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

April 7, 2024

Study Completion Date

July 31, 2024

Conditions

Infections Caused by Anaerobic BacteriaRenal Impairment

Interventions

DRUG

Levornidazole Disodium Phosphate for Injection

Single dose, IV

Trial Locations (1)

Unknown

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Beijing Haisha Consulting Co., Ltd

UNKNOWN

lead

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

INDUSTRY

NCT07033182 - Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment | Biotech Hunter | Biotech Hunter